131 related articles for article (PubMed ID: 32248003)
1. Discovery of new LXRβ agonists as glioblastoma inhibitors.
Chen H; Chen Z; Zhang Z; Li Y; Zhang S; Jiang F; Wei J; Ding P; Zhou H; Gu Q; Xu J
Eur J Med Chem; 2020 May; 194():112240. PubMed ID: 32248003
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of new thiazolo-pyrrolidine-(spirooxindole) tethered to 3-acylindole as anticancer agents.
Islam MS; Ghawas HM; El-Senduny FF; Al-Majid AM; Elshaier YAMM; Badria FA; Barakat A
Bioorg Chem; 2019 Feb; 82():423-430. PubMed ID: 30508794
[TBL] [Abstract][Full Text] [Related]
3. Spiro[pyrrolidine-3,3'-oxindoles] and Their Indoline Analogues as New 5-HT6 Receptor Chemotypes.
Kelemen ÁA; Satala G; Bojarski AJ; Keserű GM
Molecules; 2017 Dec; 22(12):. PubMed ID: 29240714
[TBL] [Abstract][Full Text] [Related]
4. Combined Scaffold Evaluation and Systems-Level Transcriptome-Based Analysis for Accelerated Lead Optimization Reveals Ribosomal Targeting Spirooxindole Cyclopropanes.
Rodriguez KX; Howe EN; Bacher EP; Burnette M; Meloche JL; Meisel J; Schnepp P; Tan X; Chang M; Zartman J; Zhang S; Ashfeld BL
ChemMedChem; 2019 Sep; 14(18):1653-1661. PubMed ID: 31140738
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biological Evaluation of Pyrazoline and Pyrrolidine-2,5-dione Hybrids as Potential Antitumor Agents.
Tilekar K; Upadhyay N; Meyer-Almes FJ; Loiodice F; Anisimova NY; Spirina TS; Sokolova DV; Smirnova GB; Choe JY; Pokrovsky VS; Lavecchia A; S Ramaa C
ChemMedChem; 2020 Oct; 15(19):1813-1825. PubMed ID: 32715626
[TBL] [Abstract][Full Text] [Related]
6. Fe
Maddela S; Makula A; Galigniana MD; Parambi DGT; Federicci F; Mazaira G; Hendawy OM; Dev S; Mathew GE; Mathew B
Arch Pharm (Weinheim); 2019 Jan; 352(1):e1800174. PubMed ID: 30485473
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of spiro-tetrahydrothiopyran-oxindoles by Michael-aldol cascade reactions: discovery of potential P53-MDM2 inhibitors with good antitumor activity.
Wang S; Chen S; Guo Z; He S; Zhang F; Liu X; Chen W; Zhang S; Sheng C
Org Biomol Chem; 2018 Jan; 16(4):625-634. PubMed ID: 29302672
[TBL] [Abstract][Full Text] [Related]
8. Reliability of Click Chemistry on Drug Discovery: A Personal Account.
Shankaraiah N; Sakla AP; Laxmikeshav K; Tokala R
Chem Rec; 2020 Apr; 20(4):253-272. PubMed ID: 31419056
[TBL] [Abstract][Full Text] [Related]
9. Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists.
Nomura S; Endo-Umeda K; Makishima M; Hashimoto Y; Ishikawa M
ChemMedChem; 2016 Oct; 11(20):2347-2360. PubMed ID: 27690261
[TBL] [Abstract][Full Text] [Related]
10. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity.
Al-Rashood ST; Hamed AR; Hassan GS; Alkahtani HM; Almehizia AA; Alharbi A; Al-Sanea MM; Eldehna WM
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):831-839. PubMed ID: 32208781
[TBL] [Abstract][Full Text] [Related]
11. Spiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification.
Hati S; Tripathy S; Dutta PK; Agarwal R; Srinivasan R; Singh A; Singh S; Sen S
Sci Rep; 2016 Aug; 6():32213. PubMed ID: 27573798
[TBL] [Abstract][Full Text] [Related]
12. Spiro[pyrrolidine-3,3'-oxindoles] as 5-HT
Kelemen ÁA; Satała G; Bojarski AJ; Keserű GM
Bioorg Med Chem Lett; 2018 Aug; 28(14):2418-2421. PubMed ID: 29910079
[TBL] [Abstract][Full Text] [Related]
13. Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches.
Chen M; Yang F; Kang J; Gan H; Yang X; Lai X; Gao Y
Molecules; 2018 Jun; 23(6):. PubMed ID: 29867043
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
Gicquel M; Gomez C; Garcia Alvarez MC; Pamlard O; Guérineau V; Jacquet E; Bignon J; Voituriez A; Marinetti A
J Med Chem; 2018 Oct; 61(20):9386-9392. PubMed ID: 30221935
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel steroidal spiro-oxindoles as potent antiproliferative agents.
Yu B; Shi XJ; Qi PP; Yu DQ; Liu HM
J Steroid Biochem Mol Biol; 2014 May; 141():121-34. PubMed ID: 24508598
[TBL] [Abstract][Full Text] [Related]
17. In vitro targeting of colon cancer cells using spiropyrazoline oxindoles.
Nunes RC; Ribeiro CJA; Monteiro Â; Rodrigues CMP; Amaral JD; Santos MMM
Eur J Med Chem; 2017 Oct; 139():168-179. PubMed ID: 28800455
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and discovery of highly functionalized mono- and bis-spiro-pyrrolidines as potent cholinesterase enzyme inhibitors.
Kia Y; Osman H; Suresh Kumar R; Basiri A; Murugaiyah V
Bioorg Med Chem Lett; 2014 Apr; 24(7):1815-9. PubMed ID: 24594354
[TBL] [Abstract][Full Text] [Related]
19. Optimization of antitumor modulators of pre-mRNA splicing.
Lagisetti C; Palacios G; Goronga T; Freeman B; Caufield W; Webb TR
J Med Chem; 2013 Dec; 56(24):10033-44. PubMed ID: 24325474
[TBL] [Abstract][Full Text] [Related]
20. Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
Qin M; Tian Y; Han X; Cao Q; Zheng S; Liu C; Wu X; Liu L; Meng Y; Wang X; Zhang H; Hou Y
Bioorg Med Chem; 2020 Jun; 28(11):115486. PubMed ID: 32305182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
